Activate's application is live from now through October 23, and all founders of early-stage, research-backed hardtech companies in Houston are encouraged to apply. Photo via Getty Images

Applications are officially open for a Activate's second Houston cohort.

Activate's application is live from now through October 23, and all founders of early-stage, research-backed hardtech companies in Houston are encouraged to apply. The Berkley, California-based program launched in Houston last year and recently named its inaugural Houston cohort.

“The Activate Fellowship provides an opportunity for approximately 50 scientists and engineers annually to transform into entrepreneurial leaders, derisk their technologies, define first markets, build teams, and secure follow-on funding,” says Activate’s executive managing director, Aimee Rose, in a news release. “With an average 30 percent annual growth in applications since 2015, we know there is high demand for what we do, and we’re excited to see the talent and impactful ideas that come through the pipeline this year.

The program, led locally by Houston Managing Director Jeremy Pitts, has 249 current Activate fellows and alumni that have collectively raised over $2.4 billion in public and private funding since the organization was founded in 2015.

“The success of Activate Fellows is ample evidence that scientists and engineers have the talent and drive to face global challenges head-on,” adds Activate chief fellowship officer, Brenna Teigler. “Our diverse fellows are transforming technical breakthroughs into businesses across the United States in 26 states across a range of sectors spanning carbon management, semiconductors, manufacturing, energy, chemicals, ocean tech, and more.”

The application is available online, and fellows will be selected in April of next year. The 2025 program will begin in June.

Activate is looking for local and regional early-stage founders — who have raised less than $2 million in funding — who are working on high-impact technology. Each cohort consists of 10 fellows that join the program for two years. The fellows receive a living stipend, connections from Activate's robust network of mentors, and access to a curriculum specific to the program.

------

This article originally ran on EnergyCapital.

Rice University President David Leebron was joined by dignitaries for the Oct. 30 opening ceremony of the Rice University National Security Research Accelerator laboratories in Dell Butcher Hall. Photo via Rice.edu

Rice University opens new accelerator labs focused on national security innovation

new on campus

A collaboration between Rice University and the United States Army has taken entered into a new phase with the opening of the Rice University National Security Research Accelerator laboratories in Dell Butcher Hall.

RUNSRA, which launched in 2019 with support from Army Futures Command and the Army Research Laboratory, premiered its new home on the Rice campus at a hybrid event. Most attendees tuned in via webcast while university president, David Leebron, and Provost Reggie DesRoches hosted U.S. Army Futures Command Lt. Gen. Thomas Todd III and U.S. Rep. Dan Crenshaw, R-Texas.

"The accelerator is the first-of-its-kind, collaborative research facility designed to deploy and develop new technologies for economic and national security," DesRoches says at the event. "The facility includes space for visiting Army Research Lab and (Department of Defense) scientists. We see this as a new model for truly collaborative research that brings together research teams from across the country and across agencies to work on mission-critical technologies."

"We are the only university in the world with a deployed software-defined network already in place," DesRoches continues. "The materials we will discover here with our ARL partners will be rapidly prototyped into devices and deployed."

Walter Jones, executive director of RUNSRA, is a the former executive director of the Office of Naval Research and former director of plans and programs at the Air Force Research Laboratory and joined Rice in June. The goal of the lab and the program is to research technologies to advance the Army's modernization.

"The accelerating pace of technology will continue to change our world," says Todd. "It will require us to re-examine how we compete and, if required, how we win on the future battlefield. And it will require us to develop new technologies that let us compete and win by expanding what is possible, which starts at a place like Rice University.

"I know that tremendous benefit will come from this research accelerator," Todd continues. "And truly, it's meant to be what it says, an accelerator of technologies into the hands of soldiers."

Watch below to view the press conference and ribnbon cutting.

The Rice University National Security Research Acceleratorwww.youtube.com

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”